EUVIMED · CrossrefJournal
Controlled Clinical Trials
ISSN 0197-2456 · Elsevier BV
Latest articles
Mounting a community-randomized trial: sample size, matching, selection, and randomization issues in PRISM
Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial
Assessment of blinding in clinical trials
A simple alternative confidence interval for the difference between two proportions
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
On the use and utility of the Weibull model in the analysis of survival data
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes
Patient compliance with paper and electronic diaries
The method of minimization for allocation to clinical trials
Active
Isotonic Designs for Phase I Trials
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Sample-Size Calculations for the Cox Proportional Hazards Regression Model with Nonbinary Covariates
Dietary Adherence
How to Select Covariates to Include in the Analysis of a Clinical Trial
Statistical Considerations in the Intent-to-Treat Principle
The Age-Related Eye Disease Study (AREDS)
Laboratory Data in Clinical Trials: A Statistician's Perspective
Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials
TRIPOD (TRoglitazone In the Prevention Of Diabetes): A Randomized, Placebo-Controlled Trial of Troglitazone in Women with Prior Gestational Diabetes Mellitus
Design of the Women’s Health Initiative Clinical Trial and Observational Study
Stroke Prevention Trial in Sickle Cell Anemia
Clinical perspectives on the use of composite endpoints
Some statistical methods for multiple endpoints in clinical trials
Interpreting tests for efficacy in clinical trials with multiple endpoints
An open letter to the FDA regarding changes in reporting procedures for drugs and biologies proposed in the wake of the FIAU tragedy
A note on quantifying follow-up in studies of failure time
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials
EUVIMED